Company Entasis Therapeutics Holdings Inc.
Equities
ETTX
US2936141033
Biotechnology & Medical Research
Business Summary
Number of employees: 51
Managers
Managers | Title | Age | Since |
---|---|---|---|
Manoussos Perros
CEO | Chief Executive Officer | 56 | 15-04-30 |
Ruben Tommasi
CTO | Chief Tech/Sci/R&D Officer | 58 | 15-04-30 |
David Altarac
CTO | Chief Tech/Sci/R&D Officer | 63 | 19-11-03 |
Kyle Dow
IRC | Investor Relations Contact | - | - |
Matthew Ronsheim
PRN | Corporate Officer/Principal | 52 | 20-08-31 |
Anna Diaz Triola
PRN | Corporate Officer/Principal | - | 21-07-18 |
John Mueller
PRN | Corporate Officer/Principal | 64 | 15-04-30 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
David Hastings
BRD | Director/Board Member | 62 | 18-03-31 |
Director/Board Member | 58 | 17-07-31 | |
Heather Behanna
BRD | Director/Board Member | 49 | 17-07-31 |
David Meek
CHM | Chairman | 59 | 19-06-23 |
Marianne Zhen
BRD | Director/Board Member | 55 | 22-07-10 |
Manoussos Perros
CEO | Chief Executive Officer | 56 | 15-04-30 |
Pavel Raifeld
BRD | Director/Board Member | 40 | 22-07-10 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 47,851,779 | 44,441,302 ( 92.87 %) | 0 | 92.87 % |
Company contact information
Sector
1st Jan change | Capi. | |
---|---|---|
-1.51% | 104B | |
+3.22% | 97.42B | |
+1.05% | 22.2B | |
-16.53% | 21.23B | |
-8.77% | 18.33B | |
-42.33% | 16.35B | |
-20.09% | 15.06B | |
+5.47% | 13.98B | |
+28.85% | 11.66B |